Inside information: Aiforia signs a major deal with an Italian Regional Health Authority

Aiforia Technologies Plc, Inside information, 29 June 2023 at 10:30 a.m. EEST. The Veneto Region Health Authority in Italy has selected Aiforia Technologies Plc as a partner for AI-assisted diagnostics in its clinical pathology laboratories.

The collaboration involves the use of Aiforia software in a total of 12 hospital units for the analysis of tissue samples from breast and prostate cancer patients. The three-year contract covers the analysis of up to 200,000 samples using Aiforia software and the use of an AI model development tool. The total value of the contract is over EUR 1.2 million and the payments will spread over the contract period 2023–2026. The contract also includes an option for a three-year continuation period.

The contract is part of an initiative to digitize the pathology laboratories of the Veneto region hospitals, including, for example, a laboratory information system provided by TESI Group and AI solutions for image analysis by Aiforia. The main provider in this tender is a GPI S.p.A. lead consortium, and Aiforia is one of their subcontractors.

"We are excited to serve the Veneto region with our AI solutions as part of the digitalization process of the anatomical pathology laboratories. This collaboration strengthens our position in the European clinical pathology market and contributes to the recognition that our solutions meet the needs of clinical pathology laboratories," says Jukka Tapaninen, CEO of Aiforia.

Aiforia does not publish short-term outlooks or financial targets. The company has set short- and medium-term business targets, including acquiring five customers in clinical diagnostics by the end of 2023. This agreement is a significant step towards achieving these goals.

Further inquiries

Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686 https://investors.aiforia.com/ 

Certified Adviser

UB Securities Ltd, tel. +358 9 25 380 225 

About Aiforia

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities across various fields, from oncology to neuroscience and more. Find out more at  www.aiforia.com